Educational Course on Lung Transplant Rejection

The Goal

The goal of the lung transplant rejection interactive course is to provide the latest trends and expert views on the treatment of lung BOS with GvHD and foster discussion between peers

Agenda

Download Agenda PDF

Day 1 - 14 May 2025

Arrival of participants

19.15 – 19.30
Meeting in the lobby

19.30
Dinner

Day 2 - 15 May 2025

09:00 – 09:15
Welcome and introduction - Therakos International Healthcare Stakeholders Engagement

09:15 – 09:30
ECP in lung transplantation: where are we now in managing LuTx complications? - Prof Peter Jaksch

09:30 – 10:15
Extracorporeal photopheresis in lung transplantation – how to prevent and treat LuTx complications - Prof Andrew Fisher

10:15 – 10:30
Interactive discussion

10:30 – 10:45
Coffee break

10:45 – 11:30
Patient selection under times of changing definitions – the Hannover approach; Patient selection and treatment algorithm - Dr Mark Greer

11:30 – 11:45
Interactive discussion

11:45 – 12:15
Vienna experience and future directions - Prof Peter Jaksch

12:15 – 12:30
Interactive discussion

12:30 – 13:30
Lunch

13:30 – 14:00
ECP is a treatment that can stabilize lung function in chronic lung allograft disfunction - Dr Saskia Bos

14:00 – 14:15
ECP in Lung Transplantation: a patient perspective - Beate Königswieser (patient)

14:15 – 14:45
Patient cases discussion - All

14:45 – 15:00
Final Remarks and Close - Prof Peter Jaksch

BOS: Bronchiolitis obliterans syndrome, ECP: Extracorporeal Photopheresis, LuTx: Lung Transplantation

Hosted by

Prof Peter Jaksch

Head of Lung Transplant Unit, Vienna Medical Hospital, Vienna, Austria

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals

Our Centres of Excellence (CoE) Programme is for customers only. If you are interested in attending our CoE courses please contact your Sales Representative.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.